MedTrace Logo

Alteplase for Percutaneous Treatment of Loculated Abdominopelvic Abscesses

NCT00284739 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 20

Last updated 2015-02-26

Study results available
· View outcomes & findings →

Summary

Intracavitary injection of low dose alteplase into loculated abdominopelvic abscesses will reduce the duration of percutaneous drainage and increase the proportion of successful drainages.

Conditions

  • Abdominal Abscess
  • Pelvic Abscess

Interventions

DRUG

Alteplase

2mg or 4mg given twice daily for three days into loculated abscess

OTHER

saline

saline injection twice daily for three days

Sponsors & Collaborators

  • Genentech, Inc.

    collaborator INDUSTRY

  • Kaiser Permanente

    lead OTHER

Principal Investigators

  • Hyo-Chun Yoon, MD, PhD · Kaiser Permanente

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2006-02-28
Primary Completion
2007-10-31
Completion
2007-10-31

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00284739 on ClinicalTrials.gov